Item 1(a). | Name of Issuer: |
Agile Therapeutics, Inc. (the “Issuer”)
Item 1(b). | Address of Issuer’s Principal Executive Offices: |
101 Poor Farm Road, Princeton, New Jersey 08540
Item 2(a). | Names of Persons Filing: |
The names of the persons filing this report (collectively, the “Reporting Persons”) are:
Perceptive Advisors LLC (“Perceptive Advisors”)
Joseph Edelman (“Mr. Edelman”)
Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)
Item 2(b). | Address of Principal Business Office or, if None, Residence: |
The address of the principal business office of each of the Reporting Persons is:
51 Astor Place, 10th Floor
New York, NY 10003
Perceptive Advisors is a Delaware limited liability company
Mr. Edelman is a United States citizen
The Master Fund is a Cayman Islands corporation
Item 2(d). | Title of Class of Securities: |
Common stock, par value $0.0001 per share (“Common Stock”)
00847L 10 0
Item 3. | If this statement is filed pursuant to§§240.13d-1(b) or240.13d-2(b) or (c), checkwhether the person filing is a: |
Not applicable.
The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages are based on 59,302,126 outstanding shares of Common Stock as reported in the Issuer’s Form10-Q filed on October 28, 2019 and an additional 5,000,000 shares purchased by the Master Fund in connection with the Issuer’s at the market offering.